043sek
0,0 %
Date:2025-11-24Time:17:29:00Latest report:Q3-2025List:SpotlightTicker:PHAL
Market Cap:25 msekEnterprise Value:28 msekNet Sales:- msekEarnings:-6,40 msekEmployees:0ISIN:SE0003359710

Ratios

10-year key figure history for PharmaLundensis turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for PharmaLundensis with index and moving average MA50 and MA200.

Stockprice:0,43
MA50:0,42
MA200:0,51
Price/MA200:-17,2 %
RSI (14):57,3
Price/MA50:2,1 %

Description

PharmaLundensis is a research company. The company's main focus is on the treatment of serious lung diseases. Diseases that the company specializes in include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced pulmonary failure. In addition to its main business, technical systems for handling drug emissions are developed. PharmaLundensis has its headquarters in Lund.

Biotechnology